- Zacks
Immunovant (IMVT) Down 1.6% Since Last Earnings Report: Can It Rebound?
Immunovant (IMVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Investor's Business Daily
After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay
Immunovant stock slumped Thursday — reversing a day-earlier jump — after pivoting its focus to what one analyst called "a backup compound."
- Zacks
Immunovant (IMVT) Falls as Q4 Earnings Miss, Pipeline in Focus
Immunovant (IMVT) declines 5% on dismal fourth-quarter fiscal 2024 results. The company names IMVT-1402 as its new lead candidate to initiate several studies for autoimmune indications.
